

References – VTE Pocketcard (November 2016)

1. Wells P, Forgie MA, Rodger MA. Treatment of venous thromboembolism. *JAMA* 2014;311(7):717-728
2. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. *Lancet* 2014;383:880-888.
3. Deep Vein Thrombosis (DVT): Treatment. Thrombosis Canada Clinical Guides. www.thrombosiscanada.ca/?page_id=18#; accessed Aug 17, 2015.
4. Scarvelis D, Wells P. Diagnosis and treatment of deep-vein thrombosis. *CMAJ* 2006;175(9):1087-1092.
5. Garcia- Sanz MT, Pena-Alvarez C, Lopez-Landeiro P, Bermo-Dominguez A, Fonturbel T, Gonzalez-Barcala FJ. Symptoms, location and prognosis of pulmonary embolism. *Rev Port Pneumol* 2014;20(4):194-199.
6. Thrombosis Canada DVT Patient Education Tool. http://thrombosiscanada.ca/websiteResources/EducationalSheets/M159_You_Have_a_DVT.pdf accessed Aug 17, 2015
7. Thrombosis Canada PE Patient Education Tool www.thrombosiscanada.ca/?page_id=18# accessed Aug 17, 2015
8. Browse NL, Thomas ML. Source of non-lethal pulmonary emboli. *Lancet* 1974;1:258-259.
9. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 2004;126(3)(Suppl):338S-400S.
10. Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. *Lancet* 1997;350(9094):1795-1798.
11. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. *N Engl J Med* 2003;349:1227–1235.
12. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. *Lancet* 2012;379:1835-46.
13. Kearon C. A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism. *J Thromb Haemost* 2012;10:507-11
14. Kearon C, Akl EA, Ornelas J et al. Antithrombotic therapy for VTE Disease: CHEST Guideline and Expert Panel Report. *Chest* 2016;149(2):315-352
15. Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med* 2010;363:2499-2510.
16. Einstein PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med* 2012;366:1287-97.
17. Agnelli G, Buller H, Cohen A, Curto M, Gallus AS, Johnson M et al. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013;369:799-808.
18. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med* 2009;361:2342-52.
19. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Treatment of acute venous thromboembolism with dabigatran versus warfarin an pooled analysis. *Circ* 2014;129:764-772.
20. Canadian Pharmacists Association. RxTx: drug Monographs Heparin, Available at: <https://www.e-therapeutics.ca/search> (accessed Oct 20, 2016)
21. Canadian Pharmacists Association. RxTx: drug Monographs Dalteparin, Available at: <https://www.e-therapeutics.ca/search> (accessed Oct 20, 2016)

22. Canadian Pharmacists Association. RxTx: drug Monographs Enoxaparin, Available at: <https://www.e-therapeutics.ca/search>(accessed Oct 20, 2016)
23. Canadian Pharmacists Association. RxTx: drug Monographs Tinzaparin, Available at: <https://www.e-therapeutics.ca/search> (accessed Oct 20,2016)
24. Canadian Pharmacists Association. RxTx: drug Monographs Fondaparinux, Available at: <https://www.e-therapeutics.ca/search#>(accessed Oct 20, 2016)
25. Canadian Pharmacists Association. RxTx: drug Monographs Coumadin, Available at: <https://www.e-therapeutics.ca/search> (accessed Oct 20, 2016)
26. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ et al. Chest 2012;141(2)(Suppl):e152S-e184S.
27. Bungard TJ, Yakiwchuk E, Foisy M, Brocklebank C. Drug interactions involving warfarin: practice tool with practical management tips. CPJ 2011;144(1):21-25e.9. Also: <http://www.cpjournal.ca/doi/pdf/10.3821/1913-701X-144.1.21> Accessed May 15, 2012.
28. Xarelto® Product Monograph, Bayer Inc, Toronto, Ontario. Revision Sept 1, 2016
29. Eliquis® Product Monograph , Pfizer Canada Inc, Kirkland, Quebec and Bristol-Myers Squibb Canada, Montreal, Quebec. Revision June 16, 2016
30. Pradaxa® Product Monograph, Boehringer Ingelheim Canada Ltd.k Burlington, Ontario. Revision August 11, 2016
31. Moore KT, Vaidyanathan S, Damaraju CV, Fields LE. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Clin Pharmacol in Drug Development 2014;3(4):321-327.
32. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013;75:476-87.
33. Praxbind Product Monograph, Boehringer Ingelheim (Canada) Ltd, Burlington, Ontario. Date of Approval April 29, 2016. Available at: http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/PraxbindPMEN.pdf Accessed September 19, 2016.
34. Advisory Committee Briefing Document: Pradaxa, Boehringer Ingelheim. August 27, 2010: pages 60-61.
35. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE Disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2)(Suppl):e419S-e494s.
36. CADTH Rapid Response Report: Risk Factors to Consider for extended anticoagulant therapy: A review of guidelines. Context and Policy Issues, Feb 11 2013.
37. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin or placebo in venous thromboembolism. N Engl J Med 2013;368:709-18.
38. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708.
39. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. Aspirin for preventing the recurrence of venous thromboembolism N Eng J Med 2012;366:1959-1967.
40. Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012;367:1979-1987.
41. Bungard TJ, Bolt J, Thomson P, Semchuk W, Lowerison J. Checklists for the use of novel oral anticoagulants by the front line clinician. CPJ 2015;148(5):241-245.